In an exchange filing, the Pune-based drugmaker said it is the first Indian company to exclusively distribute and ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
Semaglutide is used as an adjunct to diet and physical activity for adults with obesity or overweight conditions accompanied ...
Switching From Tirzepatide to semaglutide for weight loss? This article was reviewed by Lynn Marie Morski, MD, JD. Key takeaways: You can switch from tirzepatide to ...
The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...
On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...
The semaglutide market offers major opportunities in expanding obesity treatments and oral formulations, capitalizing on ...
Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...
The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...
1d
FDA approves Novo Nordisk's Wegovy(R) pill, the first and only oral GLP-1 for weight loss in adults
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy (R) pill, the first oral GLP-1 medicine for obesity in the US. (3) Wegovy (R) pill is used ...
Bengaluru: New findings presented at ObesityWeek® 2025 have unveiled promising results for an investigational daily pill ...
The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback